Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Austria Health Focus.
Medical Tubing Market to Reach US$ 23.55 Billion by 2031, Driven by Smart Technology Integration and Growing Demand
GlobeNewswire, Inc.
·
January 22, 2025
US & Canada, Jan. 22, 2025 (GLOBE NEWSWIRE) -- According to a comprehensive report from The Insight Partners,“Medical Tubing Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report” The...
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
GlobeNewswire, Inc.
·
April 2, 2025
NEWTON, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of...
Hospital Mobile X-Ray Market Set to Reach US$ 5.29 Billion by 2031, Driven by Rising Chronic Conditions and Technological Advancements
GlobeNewswire, Inc.
·
January 22, 2025
US & Canada, Jan. 22, 2025 (GLOBE NEWSWIRE) -- According to a comprehensive report from The Insight Partners,“Hospital Mobile X-Ray Market Size and Forecast (2023–2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report” The...
Britain expands import ban on EU meat, dairy amid disease threat
MENAFN
·
April 12, 2025
(MENAFN) The UK government has announced an immediate expansion of its ban on personal imports of meat and dairy products, now affecting all countries within the European Union. This measure, which takes effect on Saturday, is a direct response to...
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes
GlobeNewswire, Inc.
·
April 1, 2025
PURCHASE, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented biomarker results from the...
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
GlobeNewswire, Inc.
·
April 1, 2025
MINDFuL Phase II Blinded, Randomized, Placebo-Controlled Data Anticipated June 2025 Boca Raton, Florida, April 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company...
Nitrase Therapeutics Presents Preclinical Data from Multiple Studies Demonstrating Its Antibody Prevents Pathological Spread of Parkinson’s Disease in an Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference
GlobeNewswire, Inc.
·
April 1, 2025
- NDC-0524 is a First-in-class Monoclonal Antibody with High Selectivity for Nitrated Alpha-synuclein (nSyn) and is Expected to Begin a Randomized Phase 1/2a Trial in the Fourth Quarter of 2025 - Elevated nSyn is Found in Patients with Parkinson’s...
Strategic update on the progress and development of Molecure's key clinical projects in 2024
GlobeNewswire, Inc.
·
March 28, 2025
Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:...
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
GlobeNewswire, Inc.
·
March 27, 2025
NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that data from the...
Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025
GlobeNewswire, Inc.
·
April 1, 2025
Solengepras showed evidence of potential benefit in functional and non-motor symptoms versus placebo as measured by MDS-UPRDS Parts I, II, NMSS, and ESS, consistent with its novel non-dopaminergic mechanism of action This investigational treatment...
Nanox to Present New Data Featuring AI Bone Solution at Four Medical Conferences through June 2025 across Europe
GlobeNewswire, Inc.
·
March 26, 2025
ADOPT Study Findings Highlight Nanox.AI’s Role in Enhancing Fracture Detection and Healthcare Cost Savings PETACH TIKVA, Israel, March 26, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical...
New Data to Be Presented at Upcoming Congresses Showcase Cerevance's Advanced Clinical Program in Parkinson’s Disease and Deep Pipeline for CNS-based Disorders
GlobeNewswire, Inc.
·
March 27, 2025
Topline results from Phase 2 ASCEND trial of solengepras as a monotherapy treatment for early-stage Parkinson’s to be presented First presentation of data from Phase 1 trial of novel KCNK13 inhibitor for CNS diseases targeting neuroinflammation...
Industry Leaders Are ‘All In’ On Pharmacy Interoperability
GlobeNewswire, Inc.
·
March 19, 2025
VIENNA, Va., March 19, 2025 (GLOBE NEWSWIRE) -- The Sequoia Project, a non-profit and trusted advocate for nationwide health information technology (health IT) interoperability, today announces the official launch of the Pharmacy Workgroup as part...
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025
GlobeNewswire, Inc.
·
March 25, 2025
PURCHASE, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, will be presenting biomarker results...
NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)
GlobeNewswire, Inc.
·
March 25, 2025
SANTA ANA, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic...
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)
GlobeNewswire, Inc.
·
March 25, 2025
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19th International...
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference
GlobeNewswire, Inc.
·
March 24, 2025
CAMBRIDGE, Massachusetts, March 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded...
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
GlobeNewswire, Inc.
·
March 18, 2025
August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Company expects to have sufficient cash to fund...
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire, Inc.
·
March 25, 2025
Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026 4WARD trial protocol refined, increasing confidence in successful outcome...
Transforming Public Health through Strategic Taxation
Asian Development Bank
·
March 27, 2025
Description As the world deals with multiple public health and economic crises, innovative solutions are urgently needed. Health taxes, such as excise taxes on tobacco, alcohol, and sugary beverages, have emerged as a powerful tool to address...